Clinical trial NCT00402740: Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)
Official title: Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carotid Artery Disease
Keywords: Carotid
Artery
Disease
Stent
PROTECT
XACT
EMBOSHIELD
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2006-11-22
Enrollment: 322
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the long-term safety and efficacy of the Xact™ Rapid Exchange Carotid Stent System used in conjunction with the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5) and the Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3), in the treatment of atherosclerotic carotid artery disease in high-surgical risk subjects.


Eligibility criteria: Inclusion Criteria Subject must be ≥ 18 years of age.

Subject has the ability to cooperate with study procedures and agrees to return for all required follow-up visits, tests and exams.

Female subjects of childbearing potential must have a documented negative pregnancy test within 30 days prior to the index procedure.

Subjects taking warfarin may be included if their dosage is reduced before the index procedure to result in an INR of 1.5 or less. Warfarin may be restarted to therapeutic dose after the index procedure.

The subject must sign a written informed consent prior to the initiation of any study procedures, using a form that is approved by the Institutional Review Board (IRB) or Medical Ethics Committee (EC).

The life expectancy of the subject is at least two years.

The subject has a lesion located in the internal carotid artery (ICA); the carotid bifurcation may be involved.

The target lesion is intended to be treated with a single stent.

Target ICA vessel diameter must be visually estimated to be:

* ≥2.5 mm and ≤7.0 for the Emboshield Pro (Gen 5)
* ≥ 2.8 mm and ≤6.2 for the Emboshield (Gen 3)

And

* ≥4.0 mm and ≤9.0 mm for the Xact Stent treatment area.

The subject has a carotid artery stenosis determined by ultrasound or angiography (visual estimate) to be:

* ≥50% for symptomatic subjects

Or

* ≥80% for asymptomatic subjects

High-risk inclusion criteria for either anatomical or co-morbid risk factors are present. The subject must fulfill at least one of the criteria, Category I or II risk factors, listed below to meet the inclusion criteria.

Category I Anatomic Risk Factors

* Previous radiation treatment to the neck or radical neck dissection
* Target lesion is at or above the second vertebral body C2 (level of jaw)
* Inability to extend the head due to cervical arthritis or other cervical disorders
* Tracheostomy or tracheal stoma
* Laryngectomy
* Contralateral laryngeal nerve palsy
* Severe tandem lesions

Category II Co-morbid Risk Factors

* Previous CEA with significant restenosis (as defined for symptomatic or asymptomatic subjects)
* Total occlusion of the contralateral carotid artery
* Left ventricular ejection fraction \< 35%
* Congestive Heart failure New York Heart Association (NYHA) Functional Class III or higher
* Dialysis dependent renal failure
* Canadian Cardiovascular Society Angina Classification III or higher or unstable angina
* Requires coronary artery bypass surgery, cardiac valve surgery, peripheral vascular surgery, or abdominal aortic aneurysm repair within 60 days

  •≥80 years of age
* Myocardial infarction within previous 6 weeks
* Abnormal stress test. Treadmill, thallium or dobutamine echo are acceptable. The stress tests should be sufficiently abnormal to place the subject at increased risk for CEA. This includes subjects with two or more proximal diseased coronary arteries of \>70% stenosis that have not or cannot be revascularized or \<30 days since revascularization.
* Severe pulmonary disease, including at least one of the following: requires chronic O2 therapy; resting PO2 ≤60 mm Hg, Hematocrit ≥50%, FEV₁ or DLCO ≤50% of normal.

Exclusion Criteria

* The subject is participating in another investigational trial that would interfere with the conduct or result of this study.
* The subject has dementia or a neurological illness that may confound the neurological evaluation.
* Total occlusion of the target vessel.
* There is an existing, previously placed stent in the target artery.
* The subject has a known life-threatening allergy to the contrast media that cannot be treated.
* Subject has history of intolerance or allergic reaction to any of the study medications including aspirin, Clopidogrel bisulfate (Plavix®) or Ticlopidine (Ticlid®), heparin or Bivalirudin (Angiomax™). Subjects must be able to tolerate a combination of aspirin and Clopidogrel or aspirin and Ticlopidine.
* The subject has a GI bleed that would interfere with antiplatelet therapy.
* The subject has known cardiac sources of emboli, including but not limited to current or past history of paroxysmal or sustained atrial fibrillation (treated or untreated), valve replacement, etc.
* Subject has Hemoglobin (Hgb) less than 8 gm/dL (unless on dialysis), platelet count \<50,000/mm3, or known heparin associated thrombocytopenia.
* The subject has a history of bleeding diathesis or coagulopathy including thrombocytopenia or an inability to receive heparin or Bivalirudin (Angiomax™) in amounts sufficient to maintain an ACT of \>250, or will refuse blood transfusion.
* The subject has atherosclerotic disease involving adjoining vessels that precludes safe placement of the guiding catheter or sheath.
* The subject has other abnormal angiographic findings that indicate the subject is at risk for a stroke due to a problem other than that of the target lesion, such as: ipsilateral arterial stenosis greater in severity than the target lesion, cerebral aneurysm, or arteriovenous malformation of the cerebral vasculature.
* There is evidence of a carotid artery dissection prior to the initiation of the index procedure.
* There is an angiographically visible thrombus.
* There is any condition that precludes proper angiographic assessment, placement of the cerebral protective system or makes percutaneous arterial access unsafe, e.g. morbid obesity, sustained systolic blood pressure \>180 mm Hg, tortuosity, occlusive disease, vessel anatomy, or aortic arch anatomy.
* Occlusion (TIMI 0 flow), or string sign of the ipsilateral common or internal carotid artery.
* There is evidence of bilateral carotid stenosis that would require intervention within 30 days of the index procedure.
* There is evidence of a stroke within the previous 30 days of the index procedure.
* There is a planned treatment of a non-target lesion within 30 days post-index procedure.
* There is a history of intracranial hemorrhage within the previous 3 months, including hemorrhagic transformation of an ischemic stroke.
* There is a history of an ipsilateral stroke with fluctuating neurologic symptoms within one year of the index procedure.

Primary outcomes:
measure: Kaplan-Meier Estimate of Freedom From the Composite of Any Death, Stroke and MI During the 30 Day Post Procedural Period (DSMI), Plus Fatal and Non-fatal Ipsilateral Stroke From 31-365 Days and Annually Thereafter for a Total of 3 Years.
timeFrame: 3 years
Secondary outcomes:
measure: Acute Device Success
timeFrame: Post-procedure
measure: Procedural Success
timeFrame: 30 Days
measure: Composite of Any Transient Ischemic Attack (TIA) and Amaurosis Fugax
timeFrame: ≤30 days
measure: Kapan-Meier Estimate of Freedom From Clinically Driven Target Lesion Revascularization Through Three Years.
timeFrame: 3 years
Other outcomes:
Locations:
city: Fremont
country: United States
facility: Washington Hospital
state: California
city: Mountain View
country: United States
facility: El Camino Hospital
state: California
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital Presbyterian
state: California
city: Stanford
country: United States
facility: Stanford University Medical Center
state: California
city: Farmington
country: United States
facility: University of Connecticut Health Center
state: Connecticut
city: Jacksonville
country: United States
facility: Memorial Hospital Jacksonville
state: Florida
city: Lakeland
country: United States
facility: Lakeland Regional Medical Center
state: Florida
city: Ocala
country: United States
facility: Munroe Regional Medical Center
state: Florida
city: Honolulu
country: United States
facility: Hawaii Permanente Medical Group-Kaiser Foundation Hospital
state: Hawaii
city: Chicago
country: United States
facility: Northwestern University Memorial Hospital
state: Illinois
city: Springfield
country: United States
facility: St. John's Hospital / Memorial Medical Center
state: Illinois
city: Fort Wayne
country: United States
facility: Parkview Hospital
state: Indiana
city: Indianapolis
country: United States
facility: St. Vincent Hospital and Health Care Center
state: Indiana
city: Houma
country: United States
facility: Terrebonne General Medical Center
state: Louisiana
city: Takoma Park
country: United States
facility: Washington Adventist Hospital
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Ann Arbor
country: United States
facility: St. Joseph Mercy Hospital
state: Michigan
city: Flint
country: United States
facility: McLaren Regional Medical Center
state: Michigan
city: Grand Blanc
country: United States
facility: Genesys Regional Medical Center
state: Michigan
city: Royal Oak
country: United States
facility: William Beaumont Hospital
state: Michigan
city: Camden
country: United States
facility: Our Lady of Lourdes Medical Center
state: New Jersey
city: Newark
country: United States
facility: St. Michael's Medical Center
state: New Jersey
city: Buffalo
country: United States
facility: Millard Fillmore Hospital-Kaleida Health Systems
state: New York
city: New York
country: United States
facility: Lenox Hill Hospital
state: New York
city: Raleigh
country: United States
facility: WakeMed Hospital
state: North Carolina
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
city: Allentown
country: United States
facility: Lehigh Valley Hospital
state: Pennsylvania
city: Harrisburg
country: United States
facility: Pinnacle Health Hospital
state: Pennsylvania
city: Wyomissing
country: United States
facility: St. Joseph's Medical center
state: Pennsylvania
city: Greenville
country: United States
facility: Greenville Memorial Medical Center
state: South Carolina
city: Kingsport
country: United States
facility: Holston Valley Medical Center
state: Tennessee
city: Knoxville
country: United States
facility: Mercy Medical Center West / Baptist Hospital of East Tennessee
state: Tennessee
city: Austin
country: United States
facility: Austin Heart P.A.
state: Texas
city: Dallas
country: United States
facility: Presbyterian Heart Institute
state: Texas
city: Houston
country: United States
facility: St. Luke's Episcopal Hospital
state: Texas
city: Norfolk
country: United States
facility: Chesapeake General Hospital
state: Virginia
city: Richmond
country: United States
facility: Bon Secours St. Mary's Hospital
state: Virginia
city: Milwaukee
country: United States
facility: St. Luke's Medical Center
state: Wisconsin
Study officials:
affiliation: Wayne State University Stroke Program
name: Seemant Chaturvedi, MD
role: STUDY_CHAIR
affiliation: Columbia University
name: William A Gray, MD
role: STUDY_CHAIR
affiliation: University of Wisconsin, Madison
name: Jon Matsumura, MD
role: STUDY_CHAIR
References: